Sees FY24 EBITDA between $5.8 million and $25.0 million and Adjusted EBITDA between $15.8 million and $35.0 million.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORGO:
- Organogenesis achieves primary endpoint in Phase 3 trial of ReNu
- Medicare Administrators looking to ‘drastically shake up’ wound care, says BTIG
- Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
- Organogenesis announces favorable court ruling dismissing securities fraud case
- Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case